2018
From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea
Sinha C, Bakshi N, Ross D, Krishnamurti L. From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. PLOS ONE 2018, 13: e0199375. PMID: 29949647, PMCID: PMC6021071, DOI: 10.1371/journal.pone.0199375.Peer-Reviewed Original ResearchConceptsSickle cell diseaseGroup 1 participantsGroup 2 participantsCell diseaseSide effectsAdult SCD patientsPatient-related factorsPotential side effectsAdult patientsSCD patientsHU usePatients' attitudesAge 31Age groupsAge 18PatientsYoung adultsEfficacySignificant differencesAdultsEffective alternativeDiseaseRiskParticipantsQualitative interviews
2016
Shared Decision Making or Physician Advocate for a Particular Treatment Option: A Spectrum of Approaches to Decision Making about Disease Modifying Therapies in Sickle Cell Disease
Bakshi N, Sinha C, Ross D, Khemani K, Loewenstein G, Krishnamurti L. Shared Decision Making or Physician Advocate for a Particular Treatment Option: A Spectrum of Approaches to Decision Making about Disease Modifying Therapies in Sickle Cell Disease. Blood 2016, 128: 4757. DOI: 10.1182/blood.v128.22.4757.4757.Peer-Reviewed Original ResearchBone marrow transplantationSickle cell diseaseChronic blood transfusionsTherapeutic optionsTreatment optionsCurrent clinical conditionPhysician narrativesTherapeutic planCell diseasePatient valuesTreatment planAdult sickle cell diseaseDisease-modifying therapeutic optionsPatient’s current clinical conditionLong-term side effectsDecisional needsDisease-Modifying TherapiesMajority of patientsGroup of patientsPatient-related factorsAvailable treatment optionsGood clinical evidenceProgression of diseaseParticular treatment optionPatients' decision processes